Sinopharm Tech Holdings Limited (HK:8156)
:8156
Want to see HK:8156 full AI Analyst Report?
8156 Stock Chart & Stats
HK$0.22
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$0.22
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.12 - HK$0.44
Previous CloseN/A
Volume194.40K
Average Volume (3M)157.92K
Market Cap
HK$161.59M
Enterprise ValueHK$195.57M
Total Cash (Recent Filing)HK$6.95M
Total Debt (Recent Filing)HK$46.73M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Sep 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding633,693,050
10 Day Avg. Volume46,340
30 Day Avg. Volume157,918
Financial Highlights & Ratios
PEG Ratio1.01
Price to Book (P/B)-2.33
Price to Sales (P/S)1.40
P/FCF Ratio-11.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained, large revenue growth signals expanding product-market fit and commercial traction for a software application business. Over 2-6 months this supports scalable unit economics and provides a foundation for margin recovery if cost discipline and retention hold.
Improving Free Cash FlowAn improving free cash flow trend indicates the company is starting to convert revenue into discretionary cash, reducing reliance on external financing. If sustained, this strengthens funding for product development and working capital over the medium term.
Lean Operating BaseA very small headcount with strong revenue growth implies high revenue per employee and operational scalability typical of software models. This lean structure can enable faster margin expansion and lower incremental SG&A as sales scale, a durable structural advantage.
Bears Say
Negative Equity & High LeverageNegative equity and significant leverage create structural solvency and refinancing risk. Over months this constrains strategic flexibility, raises cost of capital, and can limit investment or M&A options until capital structure is repaired.
Negative ProfitabilityPersistently negative operating and net margins indicate core business economics are not yet self-sustaining. Without durable margin improvement, the firm will struggle to rebuild equity and fund growth internally, keeping reliance on external capital elevated.
Negative Operating Cash FlowNegative operating cash flow is a structural red flag: it implies the business currently consumes cash to run operations. Even with improving free cash flow, ongoing negative OCF forces continued external funding or asset sales, increasing execution risk over 2-6 months.
8156 FAQ
What was Sinopharm Tech Holdings Limited’s price range in the past 12 months?
Sinopharm Tech Holdings Limited lowest stock price was HK$0.12 and its highest was HK$0.44 in the past 12 months.
What is Sinopharm Tech Holdings Limited’s market cap?
Sinopharm Tech Holdings Limited’s market cap is HK$161.59M.
When is Sinopharm Tech Holdings Limited’s upcoming earnings report date?
Sinopharm Tech Holdings Limited’s upcoming earnings report date is Sep 25, 2026 which is in 127 days.
How were Sinopharm Tech Holdings Limited’s earnings last quarter?
Sinopharm Tech Holdings Limited released its earnings results on Feb 26, 2026. The company reported -HK$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.006.
Is Sinopharm Tech Holdings Limited overvalued?
According to Wall Street analysts Sinopharm Tech Holdings Limited’s price is currently Overvalued.
Does Sinopharm Tech Holdings Limited pay dividends?
Sinopharm Tech Holdings Limited does not currently pay dividends.
What is Sinopharm Tech Holdings Limited’s EPS estimate?
Sinopharm Tech Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sinopharm Tech Holdings Limited have?
Sinopharm Tech Holdings Limited has 633,693,050 shares outstanding.
What happened to Sinopharm Tech Holdings Limited’s price movement after its last earnings report?
Sinopharm Tech Holdings Limited reported an EPS of -HK$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.273%.
Which hedge fund is a major shareholder of Sinopharm Tech Holdings Limited?
Currently, no hedge funds are holding shares in HK:8156
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sinopharm Tech Holdings Limited
Sinopharm Tech Holdings Limited, an investment holding company, engages in lottery business in the People's Republic of China and Hong Kong. The company operates through Provision of Lottery-Related Services, Provision of Internet Plus Services, Manufacturing and Distribution of Personal Protective Equipment, and Other Services segments. It offers lottery-related hardware and software systems. The company is also involved in the provision of Internet plus solution services to health care, government affairs, leasing, public security, and other industries; and supply chain management, data analysis, and related services, as well as trading of goods through internet platform. In addition, it offers corporate management services; and distribution of personal protective equipment. The company was formerly known as China Vanguard You Champion Holdings Limited and changed its name to Sinopharm Tech Holdings Limited in June 2019. Sinopharm Tech Holdings Limited was founded in 1999 and is headquartered in Sha Tin, Hong Kong.
Technical Analysis
China Netcom Technology Holdings Limited
―
eBroker Group Limited
―
GET Holdings Limited
―
abc Multiactive Limited
―
Ahsay Backup Software Development Company Limited
―